Abstract:Protein homeostasis (proteostasis) requires the timely degradation of misfolded proteins and their aggregates by protein quality control (PQC), of which molecular chaperones are an essential component. Compared with other cell types, PQC in neurons is particularly challenging because they have a unique cellular structure with long extensions. Making it worse, neurons are postmitotic, i.e., cannot dilute toxic substances by division, and, thus, are highly sensitive to misfolded proteins, especially as they age. Failure in PQC is often associated with neurodegenerative diseases, such as Huntington's disease (HD), Alzheimer's disease (AD), Parkinson's disease (PD), and prion disease. In fact, many neurodegenerative diseases are considered to be protein misfolding disorders. To prevent the accumulation of disease-causing aggregates, neurons utilize a repertoire of chaperones that recognize misfolded proteins through exposed hydrophobic surfaces and assist their refolding. If such an effort fails, chaperones can facilitate the degradation of terminally misfolded proteins through either the ubiquitin (Ub)-proteasome system (UPS) or the autophagy-lysosome system (hereafter autophagy). If soluble, the substrates associated with chaperones, such as Hsp70, are ubiquitinated by Ub ligases and degraded through the proteasome complex. Some misfolded proteins carrying the KFERQ motif are recognized by the chaperone Hsc70 and delivered to the lysosomal lumen through a process called, chaperone-mediated autophagy (CMA). Aggregation-prone misfolded proteins that remain unprocessed are directed to macroautophagy in which cargoes are collected by adaptors, such as p62/SQSTM-1/Sequestosome-1, and delivered to the autophagosome for lysosomal degradation. The aggregates that have survived all these refolding/degradative processes can still be directly dissolved, i.e., disaggregated by chaperones. Studies have shown that molecular chaperones alleviate the pathogenic symptoms by neurodegeneration-causing protein aggregates. Chaperone-inducing drugs and anti-aggregation drugs are actively exploited for beneficial effects on symptoms of disease. Here, we discuss how chaperones protect misfolded proteins from aggregation and mediate the degradation of terminally misfolded proteins in collaboration with cellular degradative machinery. The topics also include therapeutic approaches to improve the expression and turnover of molecular chaperones and to develop anti-aggregation drugs.

Modulation of Amyloid States by Molecular Chaperones

Molecular Chaperones: A Double-Edged Sword in Neurodegenerative Diseases

Protein Quality Control by Molecular Chaperones in Neurodegeneration

Possible Function of Molecular Chaperones in Diseases Caused by Propagating Amyloid Aggregates

Mechanistic Insights into the Role of Molecular Chaperones in Protein Misfolding Diseases: From Molecular Recognition to Amyloid Disassembly

Amyloid inhibition by molecular chaperones in vitro can be translated to Alzheimer's pathology in vivo

Molecular chaperones biochemistry and role in neurodegenerative diseases

Molecular chaperones as modulators of polyglutamine protein aggregation and toxicity

The therapeutic potential of chemical chaperones in protein folding diseases

Molecular Chaperones as Therapeutic Target: Hallmark of Neurodegenerative Disorders

Molecular Chaperones' Potential against Defective Proteostasis of Amyotrophic Lateral Sclerosis

Kinetic analysis reveals the diversity of microscopic mechanisms through which molecular chaperones suppress amyloid formation

Observation of reduced cytotoxicity of aggregated amyloidogenic peptides with chaperone-like molecules.

The Ubiquitin-Proteasome System and Molecular Chaperone Deregulation in Alzheimer’s Disease

Misfolding and aggregation in neurodegenerative diseases: protein quality control machinery as potential therapeutic clearance pathways

Proteins in Aggregates Functionally Impact Multiple Neurodegenerative Disease Models by Forming Proteasome-Blocking Complexes

The Molecular Chaperone αB-crystallin Enhances Amyloid β Neurotoxicity

The unhappy chaperone

Regulation by Different Types of Chaperones of Amyloid Transformation of Proteins Involved in the Development of Neurodegenerative Diseases

Protein aggregation can inhibit clathrin-mediated endocytosis by chaperone competition

Small Heat Shock Proteins, Big Impact on Protein Aggregation in Neurodegenerative Disease